Embolization occurs in ∼22%-50% of patients with infective endocarditis (IE), and death is the result in 24%-50% of patients with IE who develop embolism [1] [2] [3] [4] . Antimicrobial therapy is the only proven medical therapy known to decrease the risk of embolism associated with IE. Antiplatelet agents have been of interest as adjunctive therapy in IE because of the integral role of platelets in vegetation formation, and experi-mental endocarditis studies have demonstrated the beneficial effects of the agents. Kupferwasser et al. [5] used an experimental model of endocarditis and showed that aspirin reduced the number of renal embolic events and other measurable parameters of infection severity. Antiplatelet agents were also found to improve the efficacy of antibiotic therapy in experimental endocarditis, with reductions in both vegetation weight and bacterial density in infected vegetations [5] .
Findings of this [5] and other [5] [6] [7] [8] [9] [10] experimental endocarditis studies, coupled with an understanding of IE pathogenesis in both animals and humans, prompted 2 clinical trials of aspirin as adjunctive therapy in the treatment of IE in humans. One prospective study [11] included only 9 patients, which thus made it difficult to draw conclusions from the findings of the investi- gation. A second large, multicenter, prospective, randomized, double-blind, placebo-controlled trial examined the use of high-dose aspirin (325 mg) as adjunctive therapy in combination with antimicrobial treatment of IE [12] . There was no difference in embolic events between the aspirin and placebo groups; however, increased bleeding complications were noted among aspirin recipients. The current recommended IE treatment paradigm has been influenced by the findings of this investigation and encourages physicians to avoid adjunctive antiplatelet therapy [2] .
We hypothesized that antiplatelet therapy could alter the risk of embolism associated with IE among patients who had received continuous daily antiplatelet therapy before onset of valvular infection, and therefore, we examined a retrospective cohort of patients with IE to determine the validity of this hypothesis.
METHODS

Patients.
The study cohort included all adult patients (у18 years old) with a confirmed diagnosis of IE treated at the Mayo Clinic (Rochester, MN) during 1980-1998. Prospective records maintained by the Division of Infectious Diseases of all patients treated for IE and the diagnostic codes for IE used by the Medical Index Retrievals-Health Sciences Research were used to obtain a list of patients with probable diagnosis of IE. The medical records were screened by physician reviewers to confirm a diagnosis of IE, using the modified Duke criteria [13] . The study was approved by the Mayo Clinic Institutional Review Board.
Data collection. Standardized data abstraction forms with detailed definitions of variables were used (Appendix). Clinical, laboratory, and outcome data were obtained from the medical records. These data were abstracted from thorough review of medical records, including daily physicians' progress notes and all subspecialty consultations. All patients were observed daily in the hospital by infectious diseases specialists and cardiology subspecialists, and additional consultations were secured when indicated. Any uncertainties in data abstraction were discussed with one of the experienced investigators (J.M.S., W.R.W., K.C., and L.M.B.).
Antiplatelet therapy. Antiplatelet therapy was defined as aspirin, dipyridamole, clopidogrel, ticlopidine, or any combination of these agents. Patients who had been receiving antiplatelet therapy at the time of hospital admission were first identified. Their medical records from prior to admission were then scrutinized for previous use of antiplatelet agents in their daily medical regimen. Patients were considered to have received continuous daily antiplatelet therapy if their exposure to these agents occurred for at least 6 months prior to diagnosis of IE and if interim medical patient records revealed the continued presence of antiplatelet agents in the medical regimen.
The duration of 6 months of antiplatelet therapy prior to diagnosis of IE was chosen to insure that this therapy preceded infection onset, including in those cases in which infection progression was more indolent.
End points. The primary end point was a symptomatic embolic event that occurred before or during hospitalization for IE. To avoid outcome ascertainment bias as a result of a varied diagnostic evaluation for emboli, we included only symptomatic emboli. Embolic events were identified by physical examination in cases of peripheral limb involvement. All other embolic events were identified by specific imaging modalities that were performed in accordance with the patient's clinical symptom. We further subdivided embolic events into events that were nondisabling and those that were disabling. Nondisabling emboli were defined as events that did not cause loss of function. Transient ischemic attack and spleen, liver, kidney, and skin emboli were included in this category. Disabling emboli were defined as events that incurred a loss of functional capacity. Stroke, blindness, and major artery emboli (extremity and coronary with myocardial infarction) were included in this category. Stroke was defined by the World Health Organization definition [14] as a neurological deficit that lasted 124 h and was of presumed vascular origin. The secondary end point was all-cause mortality within the first 6 months of diagnosis of IE.
Statistical analysis. The study cohort, consisting of 600 patients, was divided into 2 groups on the basis of whether the patient had received continuous daily antiplatelet therapy for at least 6 months prior to diagnosis of IE. Baseline clinical characteristics for each group were compared by using a t test and x 2 test for continuous and categorical variables, respectively. A propensity score for antiplatelet therapy was developed using logistic regression analysis [15] to adjust for selection bias for receiving antiplatelet therapy. The dependent outcome variable was use of antiplatelet therapy for at least 6 months prior to diagnosis of IE. Stepwise backward and forward selection procedures were used to identify the most predictive baseline characteristics that were associated with likelihood of receiving antiplatelet therapy. Significant differences in baseline characteristics between the 2 groups, which were identified by univariate analysis, were entered into this model.
Multivariable logistic regression analysis was used to assess the influence of antiplatelet therapy on embolic events. The dependent outcome variable was a symptomatic embolic event. Baseline characteristics between the 2 groups, which differed significantly in univariate analyses ( ), were used in the P ! .05 adjustment model (Appendix), in addition to the propensity score previously mentioned. To account for possible competing risk of 6-month mortality, a separate analysis that included the same statistical methods was performed for a subset of the cohort who died within 6 months after diagnosis of IE. ORs for symptomatic embolic events were determined for use of antiplatelet therapy and no use of antiplatelet therapy. Interaction testing was performed between antiplatelet therapy and several cardiovascular comorbidities known to influence embolic risk. Statistical significance was defined as a 2-tailed P value !.05. All analyses were performed using Stata software, version 8.2 (Stata).
RESULTS
One hundred twenty-five patients (20.8%) received antiplatelet therapy. Aspirin was the predominant antiplatelet agent used (in 98% of patients). Among patients who received aspirin, the majority received a dosage of р81 mg/day; 10.4%, 50.6%, 2.6%, 24.7%, and 11.7% received р81 mg/day, 81 mg/day, 225 mg/ day, 325 mg/day, and у325 mg/day, respectively.
Baseline characteristics. The baseline characteristics of the study cohort are shown in table 1. Patients receiving antiplatelet therapy were slightly older, and more were men, with an increased frequency of hypertension, dyslipidemia, coronary artery disease, prior myocardial infarction, hospitalization for heart failure, prosthetic valve placement, and higher Charlson scores, compared with patients not receiving antiplatelet agents (table 1) . There were no significant differences in the prevalence of diabetes mellitus or prior history of stroke between the 2 groups. The baseline laboratory variables between the 2 groups were statistically similar, except for serum creatinine results of which the difference was not deemed clinically important. There were no differences in valves involved or types of microorganisms causing IE between the 2 groups (table 1) .
Clinical events. There were 147 symptomatic embolic events (24.5%) among 600 patients, and 87 patients (59.2%) who experienced emboli died. The predominant symptomatic embolic event was stroke (48.2%), followed by splenic embolism (29.3%), renal embolism (12.9%), and coronary embolism (8.1%). The prevalence of nondisabling and disabling embolic events was 33.3% (49 embolic events) and 47.6% (70 embolic events), respectively; 28 embolic events (19.0%) were not classified as either nondisabling or disabling because of lack of available clinical information. Embolic events occurred significantly less frequently among patients who received continuous daily antiplatelet therapy than among those who did not receive antiplatelet therapy (12.0% vs. 27.8%; ). Furthermore, among patients who expe-P ! .001 rienced embolic events, the risks of either nondisabling or disabling events were significantly less in those who had received prior, continuous daily antiplatelet therapy, compared with those who had not received antiplatelet therapy (figure 1). Among patients receiving aspirin, there was no significant difference in the risk of embolic events between individuals receiving р81 versus 181 mg/day (17.0% vs. 11.1%;
). P p .42 The unadjusted OR for risk of symptomatic emboli with use of antiplatelet therapy was 0.35 (95% CI, 0.20-0.63;
). P ! .001 After adjustment for several covariates known to influence risk of embolism, including propensity score for receiving antiplatelet therapy, the adjusted OR for a symptomatic embolic event was 0.36 (95% CI, 0.19-0.68;
) for antiplatelet therapy P p .002 use (table 2) .
There was no significant difference in the proportion of patients who died during the first 6 months after diagnosis of IE, regardless of whether they received continuous daily antiplatelet therapy (23.4% of patients who received therapy vs. 23.9% who did not receive therapy;
). However, among patients P p .90 who died within 6 months after diagnosis of IE, risk of an embolic event prior to death was reduced with use of antiplatelet therapy (adjusted OR, 0.29; 95% CI, 0.10-0.81; ) P p .02 (table 2) .
Among patients who received antiplatelet therapy, embolic events occurred significantly less frequently in those who did not have hypertension, history of myocardial infarction, or coronary artery disease than in those who had these comorbidities (table 3) . There was an interaction for incidence of embolism between use of continuous antiplatelet therapy and vascular comorbidities of hypertension ( ), coronary artery dis-P p .001 ease ( ), and history of myocardial infarction ( P p .01 P p ). There were no interactions for incidence of embolism .028 between use of continuous antiplatelet therapy and age, sex, concurrent receipt of warfarin therapy, diabetes mellitus, or history of stroke.
DISCUSSION
This study demonstrated, that among patients who developed IE, embolic events and related morbidity occurred significantly less in those who received prior, continuous daily antiplatelet therapy. The odds of experiencing a symptomatic embolic event were 64% less for antiplatelet therapy recipients than for patients who did not receive antiplatelet therapy.
The perceived benefit of continuous daily antiplatelet therapy revealed in our study may have been a result of several different pathogenic mechanisms associated with host and/or microbial factors. A number of investigations have demonstrated that aspirin may attenuate microbial virulence factors [6] and reduce bacterial adherence to biomatrix [16] , capsule formation [17] , biofilm formation [18] , vegetation growth, bacterial proliferation in vegetations, and hematogenous dissemination in experimental endocarditis [7] and matrix protein adherence [6] .
However, there was no demonstrated benefit among humans in a large, multicenter trial [12] , that examined the role of high-dose aspirin as adjunctive therapy in patients with IE. There are 2 major differences between our study and the prospective, multicenter study reported by Chan et al. [12] . First, patients in the prospective trial [12] did not receive aspirin adjunctive therapy for 130 days after infection onset. Any potential benefit of adjunctive antiplatelet therapy may not have been realized because of the delayed onset of antiplatelet therapy use. Our study, although retrospective, clearly demonstrates that antiplatelet therapy offers protection from embolic events when it has been administered prior to acquisition of IE. This is consistent with results of animal models of experimental endocarditis [5] [6] [7] [8] [9] [10] in which antiplatelet therapy was started prior to infection onset. Second, the dosages of antiplatelet agents, particularly aspirin, differed between our study and that of Chan et al. [12] . In the latter investigation, high-dose (325 mg/day) aspirin therapy was used; in contrast, the majority of patients in our study received "low-dose" (р81 mg/day) aspirin therapy. Results from animal models of experimental endocarditis suggest that higher doses of aspirin may have unexpected effects [5, 7] . In contrast to lower doses of aspirin, which diminished vegetation size and endocarditis severity, higher doses of aspirin had no such effects, possibly because of inhibition of prostacyclin synthesis [5] . This may partly explain the lack of effect of high-dose aspirin therapy observed in the study by Chan et al. [12] . Among patients who received prior, continuous daily antiplatelet therapy, those with cardiovascular comorbidities, such as hypertension, coronary artery disease, and previous myocardial infarction, did not experience the same benefit. There are several plausible explanations for this unanticipated observation. Compared with healthy individuals, those with cardiovascular risk factors may exhibit a heightened level of platelet activation that may not be entirely inhibited by aspirin [19, 20] . It is estimated that 10%-20% of patients who experience an arterial thrombotic event and are then treated with aspirin experience a recurrent arterial thrombotic event during longterm follow-up, and this phenomenon is termed "aspirin resistance" [19] [20] [21] . Smoking and hyperlipidemia have been shown to interfere with the effects of aspirin on platelet activation by increasing the production of prostaglandin F2-like compounds, known as isoprostanes [20, 22] . Isoprostanes can induce vasoconstriction and have prothrombotic effects by amplifying the response to other agonists [23] . These mechanisms result in aspirin insensitivity at usual preventive doses. Additionally, other medicines can alter the physiologic effects of aspirin. In particular, regular consumption of certain nonsteroidal anti-inflammatory drugs, including ibuprofen and indomethacin, appears to antagonize the antiplatelet effects of aspirin and may worsen outcomes in patients who are also administered aspirin [24] [25] [26] . Finally, a genetic component may predict aspirin resistance in certain groups. Several single nucleotide polymorphisms have been linked to changes in platelet function, thrombosis, and increased risk for coronary artery disease [20, [27] [28] [29] . Combined, these factors may interfere with the potential benefits of aspirin in IE patients with cardiovascular comorbidities.
There was no difference in 6-month mortality between patients in our study who received continuous daily antiplatelet therapy and those who did not. This can be explained, in part, by an increased number of comorbid conditions that characterized patients who received antiplatelet therapy. The mean age of the group that received antiplatelet therapy was 3 years older, and the group had a 50% higher prevalence of diabetes mellitus, almost twice the rate of coronary artery disease, almost 3 times the rate of myocardial infarction, higher rate of prior stroke and congestive heart failure, and a higher Charlson score.
Among the total symptomatic embolic events reported in several series [30] [31] [32] [33] [34] [35] , the prevalence of coronary artery embolism varied by as much as 10-fold (range, 1.37%-15%). The 8.1% prevalence described in our study is within the range of these previously reported values. A separate multivariable logistic regression analysis, with censoring of coronary embolic events, was also performed. This reanalysis demonstrated that antiplatelet therapy was still associated with a reduced rate of embolism (OR, 0.33;
); the same model was used as P p .002 described in the manuscript.
There are several limitations to our study. The Mayo Clinic is a large, tertiary care facility, and there is potential for referral bias among patients who are referred for admission to these larger facilities [36, 37] . Our findings are based on data collected in a retrospective study design; although all charts were available for review, completeness and accuracy of the patient records cannot be guaranteed. We did not collect data on complications involving bleeding in our study. A low-dose aspirin regimen (р81 mg/day) was used by the majority of patients in our study, and the expected risk of bleeding with this dose is small; extensive clinical trial data [38, 39] have previously demonstrated that the risks of minor and major bleeding episodes that are attributable to low-dose aspirin therapy are only 3.2% and 2.6%, respectively. Our investigation did not include quantitative measurements of vegetation size using echocardiographic examination. We found that the mode of echocardiographic examination and windows of measurement of vegetations varied substantially, precluding an objective comparison of echocardiographic data. However, serial transesophageal echocardiographic examination, performed in 46 of 115 cases in the study by Chan et al. [12] , demonstrated a decrease in the vegetation size in both treatment groups (the group receiving aspirin and the group receiving a placebo), and the absolute and percent change did not differ between the 2 treatment groups.
Although the results of our investigation meet criteria for likely causality of an association between antiplatelet therapy and decreased occurrence of embolic events during IE [40] ;
150% reduction in embolic risk makes it likely to be a casual association. Moreover, our study findings are strongly supported by the findings of studies of animal endocarditis.
Continuous daily antiplatelet therapy appears to be associated with an observed decreased incidence of embolic events when IE develops. Thus, it is conceivable that continuous daily antiplatelet therapy could prove to be beneficial in selected patients with known underlying valvular abnormalities who are at increased risk of developing IE.
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APPENDIX MODEL FOR MULTIVARIABLE LOGISTIC REGRESSION
CONTINUOUS
Age, baseline hemoglobin level, baseline peripheral WBC count, baseline creatinine level, Charlson score, and propensity score for antiplatelet therapy.
CATEGORICAL
Sex; race; New York Heart Classification; anticoagulation therapy; history of coronary artery disease, injection drug abuse, myocardial infarction, congestive heart failure, peripheral vascular disease, stroke, diabetes mellitus, and malignancy; prosthetic valve; valve involved (aortic, mitral, tricuspid, and pulmonary); and organisms (gram-negative bacteria, Haemophilus species, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, Kingella species, fungi, Staphylococcus aureus, viridans group streptoccoci, enterococci, coagulase-negative staphylococci, and multiple organisms).
VARIABLES
PROPENSITY
Propensity "to receive antiplatelet therapy." Age, sex, coronary artery disease, myocardial infarction, PVD, diabetes mellitus, stroke, hypertension, hypercholesterolemia, smoking, and other thrombotic states.
Negative propensity. Bleeding tendency or history of bleeding (gastrointestinal, CNS, or other major site of bleeding).
INTERVENTION (ANTIPLATELET THERAPY)
Name, dose, and duration of therapy.
OUTCOME
Embolic events. First disabling and first nondisabling symptomatic embolic events.
Symptomatic nondisabling emboli. Patients with symptoms as a direct consequence of embolic phenomenon that were not disabling (includes transient ischemic attack, joint, major artery, spleen, liver, kidney, and skin emboli).
Disabling. Stroke, blindness, or major artery emboli (extremities requiring amputation, mesenteric with infarction, and coronary with myocardial infarction).
